Briefing
ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
104 (58%) ctDNA+ within 2 years after RC, 63% of those within 4 months.
- Design: Danish multicenter, open-label, single-arm phase 2. MIBC after NAC and RC. ctDNA+ started atezolizumab up to 1 year; ctDNA- received IO only if imaging showed metastases.
- n: 192 enrolled, 178 assessable, median FU 34 months
- Assay: Serial tumor-informed plasma ctDNA (not utDNA)